tbuckley/cabot-search huggingface dataset:
Adverse Effects of Proton Pump Inhibitors in Chronic Kidney Disease
Authors: Pan Zhao, Zhenman Wei, Jin Han
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
AB0530 Efficacy and Safety of Multi-Target Therapy Using a Combination of Cyclophosphamide and Tacrolimus in Patients with Refractory Lupus Nephritis: A Prospective, Single-Arm, Open-Label Study of 13 Patients
Authors: R. Sakai, A. Shibata, K. Chino, T. Kondo, A. Okuyama, H. Takei, K. Amano
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Pulsed cyclophosphamide (pCYC) for lupus nephritis (LN) has limited effects in some cases; mycophenolate mofetil is an off-label pharmaceutical agent in Japan. <h3>Objectives</h3> To assess the effectiveness of multi-target therapy with pCYC and tacrolimus (Tac) for treating LN, including refractory cases. <h3>Methods</h3> We have done a prospective, single-arm, open-label study at our center (UMIN4893). Thirteen patients with active LN were enrolled. Prednisolone was started at 1 mg/ kg/day, aiming to reduce the dose to 10 mg/day after 6 months. Intravenous cyclophosphamide was administered as per the Euro-Lupus protocol (500 mg biweekly for 3 months). The trough concentration of Tac was adjusted to 5–10 ng/ml as per National Health Insurance. Complete remission (CR) was defined as a spot urine protein/creatinine (UPCR) ratio of &lt;0.5 g/gCr and normal eGFR or eGFR improvement as per EULAR/ERA-EDTA recommendations and KDIGO guidelines. <h3>Results</h3> The mean age was 41.5 years (male:female =2:11); UPCR, 3.4 g/gCr; serum creatinine, 1.00 mg/dl; C3, 44.8 mg/dl (90.0–140.0 mg/dl); and C4, 5.7 mg/dl (18.0–30.0 mg/dl). One, eight and three patients belonged to Classes III, IV, and IV + V, respectively, and one had no data. Eleven out of the 13 patients completed the treatment protocol; 2 patients withdrew. The CR at 6 months was 69.2% (n=9/13). Side effects, including infections, did not increase as compared to conventional therapy with pCYC, except a transient increase in serum creatinine with Tac. <h3>Conclusions</h3> Multi-target therapy such as pCYC and Tac can be a therapeutic option for refractory LN. <h3>Disclosure of Interest</h3> R. Sakai: None declared, A. Shibata: None declared, K. Chino: None declared, T. Kondo: None declared, A. Okuyama: None declared, H. Takei: None declared, K. Amano Grant/research support from: Astellas, Chugai, Pfizer, Tanabe-Mitsubishi, Consultant for: Zenyaku Kogyo, Paid instructor for: Chugai, Pfizer, Santen, Tanabe-Mitsubishi, Speakers bureau: AbbVie, Actellion, Astellas, Bristol-Myers-Squibb, Chugai, Diichi-Sankyo, Eisai, Pfizer, Tanabe-Mitsubishi
Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias
Authors: Nicole Kucine, Sachie Marubayashi, Neha Bhagwat, Efthymia Papalexi, Priya Koppikar, Marta Sanchez Martin, Lauren Dong, Marty S. Tallman, Elisabeth Paietta, Kai Wang, Jie He, Doron Lipson, Phil Stephens, Vince Miller, Jacob M. Rowe, Julie Teruya-Feldstein, Charles G. Mullighan, Adolfo A. Ferrando, Andrei Krivtsov, Scott Armstrong, Laura Leung, Stefan O. Ochiana, Gabriela Chiosis, Ross L. Levine, Maria Kleppe
Journal: Blood (2015)
Bitter sweets
Authors: Des Spence
Journal: BMJ (2008)

Soluble receptors for several cytokines have been detected in body fluids and are believed to modulate the cytokine response by binding the ligand and thereby reducing its bioavailability. In the case of IL-6, the situation is more complex. The receptor consists of two components, including a ligand-binding α-subunit (IL-6R, gp80, or CD126), which in its soluble (s) form (sIL-6R) acts agonistically by making the ligand accessible to the second subunit, the signal transducer gp130 (CD130). Soluble forms of both receptor subunits are present in human blood. Gel filtration of iodinated IL-6 that had been incubated with human serum revealed that IL-6 is partially trapped in IL-6/sIL-6R/sgp130 ternary complexes. sgp130 from human plasma was enriched by immunoaffinity chromatography and identified as a 100-kDa protein. Functionally equivalent rsgp130 was produced in baculovirus-infected insect cells to study its antagonistic potential on four different cell types. It was found that in situations in which cells lacking membrane-bound IL-6R were stimulated with IL-6/sIL-6R complexes, sgp130 was a much more potent antagonist than it was on IL-6R-positive cells stimulated with IL-6 alone. In the latter case, the neutralizing activity of sgp130 could be markedly enhanced by addition of sIL-6R. As a consequence of these findings, sIL-6R of human plasma must be regarded as an antagonistic molecule that enhances the inhibitory activity of sgp130. Furthermore, in combination with sIL-6R, sgp130 is a promising candidate for the development of IL-6 antagonists.
AB0323 Patients with Higher Education Present Greater Improvements on Functional Status in Early Rheumatoid Arthritis
Authors: X. Jiang, M. Sandberg, S. Saevarsdottir, L. Klareskog, L. Alfredsson, C. Bengtsson
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Low socioeconomic status (SES), measured through a variety of ways (e.g. formal education, occupation, household income, ethnicity) has been associated with an increased risk of rheumatoid arthritis (RA), an elevated economic burden for patients and society, as well as a worse disease outcome. <h3>Objectives</h3> To investigate the effect of educational status (achieving a university/college degree) on the prognosis of RA overall, as well as on disease subsets based on ACPAs, in terms of DAS28, physician assessment, VAS-pain, and HAQ. <h3>Methods</h3> We used cases from the population-based EIRA study with outcomes followed-up in the Swedish Rheumatology Quality Register (N=3021). We categorized the outcomes in different ways: 1) having equal to/above <i>vs.</i> below median levels; 2) achieving low disease activity, good response, and remission <i>vs.</i> not achieving; 3) having scores decreased over the median <i>vs.</i> less than median. We calculated the ORs of those outcome categories as an effect of higher education, both at diagnosis and for the first three follow-up visits (3, 6, 12 months). <h3>Results</h3> We found patients of higher education initiated with less pain and less functional disability (VAS-pain: 49 (28-67) <i>vs.</i> 53 (33-71), p&lt;0.0001, HAQ: 0.88 (0.50-1.38) <i>vs.</i> 1.00 (0.63-1.50), p=0.001). The effects persisted across the follow-up period. They had greater chances to achieve pain remission (3-month-visit: 1.35 (1.08-1.69); 6-month-visit: 1.22 (0.95-1.56); 1-year-visit: 1.23 (1.00-1.52)) and improve to a larger extent (HAQ decrease over the median: 3-month-visit: 1.45 (1.13-1.86); 6-month-visit: 1.41 (1.07-1.86); 1-year-visit: 1.43 (1.12-1.82)). <h3>Conclusions</h3> Higher educated patients experienced less pain and less functional disability starting from baseline throughout the first year receiving standard care; they achieved pain remission more and attain greater improvements on physical function as compared to less educated patients. We could not identify any distinct effects of educational background on disease activity related outcomes. <h3>Disclosure of Interest</h3> None declared
Hope
Authors: Lubna Wani
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FRI0154 Incidence of Cancers in Patients with Rheumatoid Arthritis and a History of Cancer Treated with Rituximab or Abatacept
Authors: J.E. Gottenberg, J. Morel, P. Ravaud, T. Bardin, P. Cacoub, A. Cantagrel, B. Combe, A. Constantin, M. Dougados, R.M. Flipo, B. Godeau, E. Hachulla, X. Le Loet, T. Schaeverbeke, J. Sibilia, I. Pane, G. Baron, X. Mariette
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Patients with a history of cancer were excluded from pivotal clinical trials evaluating biologics. Therefore, only registries can inform us on the incidence of cancers in such patients treated with a biologic. <h3>Methods</h3> Registries of the French Society of Rheumatology AIR and ORA included 1985 and 1024 patients to study tolerance and efficacy of rituximab and abatacept in common practice, respectively. Cancers and serious infections were validated by analysis of the charts of patients. <h3>Results</h3> 258 patients had a history of cancer and 1552 patients did not have a history of cancer before rituximab (175 missing data). Among the 1552 patients without a history of cancer, 1549 patients had at last one follow-up visit (5344 patient-years) and 42 cancers occurred (<i>0.8 cancers/100 patient-years</i>). Among the 258 patients with a history of cancer, 257 had at least 1 follow-up visit (867 patient-years) and 26 incident cancers (<i>2.9 cancers/100 patient-years</i>), including 12 new cancers (1.3 cancers/100 patient-years) and 14 relapses of past cancers (1.6 cancers/100 patient-years). 54 patients had a history of cancer and 958 patients did not have a history of cancer before abatacept (12 missing data). Among the 958 patients without a history of cancer, 930 patients had at least 1 follow-up visit (2705 patient-years) and 36 cancers occurred (<i>1.3 cancers/100 patient-years</i>). Among the 54 patients with a history of cancer, 53 patients had at least 1 follow-up visit (152 patient-years). Four incident cancers occurred (<i>2.6 cancers/100 patient-years</i>) including 2 new cancers (1.3 cancers/100 patient-years) and 2 relapses of past cancers (1.3 cancers/100 patient-years). <h3>Conclusions</h3> The incidence of cancers in the French national registries of patients with a history of cancer treated with rituximab or abatacept, approximately two-fold that of patients without a history of cancer, is comparable to that observed in the German RABBIT registry in patients with a history of cancer and rheumatoid arthritis treated with synthetic DMARDs or rituximab. Thus, until now, the risk of recurrence of cancer in patients with a history of cancer treated with rituximab or abatacept is in the range of what is expected in these patients at higher risk of cancer. Given the relatively short follow-up, it is necessary to continue to monitor patients with a history of cancer and to keep on evaluating the benefit/risk ratio before initiating a biologic, even a non anti-TNF biologic, in such patients. <h3>Disclosure of Interest</h3> None declared
Experimental Studies Utilizing Low Flow Rates with Profound Hypothermia
Authors: D R CAIN, M COHEN
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PWE-151 A 'long, tight' laparoscopic sleeve gastrectomy is safe, effective and improves quality of life in an elderly population
Authors: GD Macaulay, M Kandasamy, D Martin
Journal: Gut (2015)

<h3>Introduction</h3> Laparoscopic Sleeve Gastrectomy (LSG) is an increasingly popular procedure for the management of obesity. Despite good evidence to support the efficacy of LSG, there is a paucity of data in relation to outcomes in the elderly. Here we present our initial experience. <h3>Method</h3> Data from 38 patients aged 60 years or over, who underwent LSG within a single surgeon experience of 712 cases between 2007 and 2013 was analysed. A "long, tight9 sleeve was performed over a 29Fr bougie. A prospectively maintained database included information on patient demographics, Body Mass Index (BMI), excess body weight loss (EBWL), complications and comorbidity resolution. Quality of life was assessed using the Impact of Weight on Quality of Life Questionnaire - Lite (IWQOL-Lite) tool. <h3>Results</h3> 12 patients were male (31.6%) and 26 were female (68.4%). The mean age at the time of surgery was 64.1 +/- 1.0 years and the mean pre-operative BMI was 44.4 +/- 2.1 kg/m<sup>2 </sup>(range 34.9 – 60.7, 95% CI). Follow-up rates were 100% at 6 months, 93% at 12 months and 74% at 24 months. Mean EBWL at 6 months, 12 months and 24 months was 64%, 72% and 80%, respectively. The prevalence of comorbidity in the cohort pre-operatively was: diabetes mellitus 57.9% (n = 22), obstructive sleep apnoea 36.8% (n = 14) and hypertension 65.8% (n = 25). Diabetes resolved in 31.8% of subjects and improved in 54.5%. Sleep apnoea resolved in 50% of patients and 28.6% reported an improvement. Hypertension resolved in 48% of our cohort, with an improvement evident in 24%. At a mean of 21.2 months, all patients who had completed the IWQOL-Lite questionnaire reported an improvement in quality of life. A lower percentage score indicates a better quality of life. The mean IWQOL-Lite score was significantly lower following a "long, tight9 LSG, 29.6% vs. 59.1% pre-operatively (p &lt; 0.001). There were no deaths or leaks within the elderly cohort. No patients required endoscopic dilatation post-operatively. One patient was re-operated on for hiatus hernia/reflux following LSG. The incidence of post-operative venous thromboembolism was higher in the elderly group following LSG, 5.3% (n = 2) vs. 0.5% (n = 3) in the 674 patients under the age of 60. <h3>Conclusion</h3> Our data supports the 9long, tight9 LSG as an option for the surgical management of obesity and metabolic disease in the elderly. It is safe and effective in terms of weight loss and comorbidity resolution within a population over 60 years of age. Furthermore, we have demonstrated an improvement in quality of life within this patient group. <h3>Disclosure of interest</h3> None Declared. <h3>Reference</h3> Willkomm CM, Fisher TL, Barnes GS, Kennedy CI, Kuhn JA. Surgical weight loss &gt;65 years old: is it worth the risk? Surg Obes Relat Dis. 2010;6(5):491-496
Dose-intensive treatment of acute myelogenous leukemia: improved survival?
Authors: G Schiller
Journal: Journal of Clinical Oncology (1995)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1995.13.7.1828 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 7602375 Dose-intensive treatment of acute myelogenous leukemia: improved survival? G SchillerxG SchillerSearch for articles by this author https://doi.org/10.1200/JCO.1995.13.7.1828 PDF "Dose-intensive treatment of acute myelogenous leukemia: improved survival?." Journal of Clinical Oncology, 13(7), pp. 1828–1830© 1995 by American Society of Clinical Oncology
FRI0366 From Symptom Onset to Effective Early Rheumatoid Arthritis Care: The General Practitioners' Perspective
Authors: S. Meyfroidt, J. Stevens, J. De Lepeleire, R. Westhovens, D. De Cock, K. Van der Elst, K. Vanhaecht, P. Verschueren
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> General practitioners (GPs) play a crucial role in the management of early rheumatoid arthritis (ERA), a disease affecting 0.8% of the population worldwide. The experiences, beliefs and attitudes of GPs with regards to the management of ERA remain unknown. <h3>Objectives</h3> To explore GPs9 experiences, beliefs and attitudes regarding ERA detection, referral and initial intensive treatment use. <h3>Methods</h3> A qualitative study was conducted using individual, in-depth, face-to-face interviews with 13 GPs. Interviews were audio-recorded, transcribed verbatim and coded using the constant comparative method. <h3>Results</h3> GPs applied many different examination techniques for ERA detection and prescribed regularly non-steroidal anti-inflammatory drugs if they suspected ERA. However, GPs felt unconfident in the detection due to symptoms of ERA often being insufficiently clear, inconclusive results of diagnostic tests and low incidence of ERA in the general practice. GPs mentioned various approaches and multiple factors determining their referral decision. Perceived referral barriers included limited access to rheumatology services and long waiting lists. GPs considered intensive treatment initiation as belonging to the expertise of rheumatologists. GP-reported key barriers to intensive treatment included patients9 resistance and non-adherence, lack of GP involvement and unsatisfactory collaboration with rheumatology services. <h3>Conclusions</h3> GPs recognised the importance of rapid detection and initial intensive treatment for ERA, but experienced various related barriers. ERA management in general practice could be improved by targeting GPs9 skills to detect ERA, better collaboration with rheumatology services and developing an ERA care pathway. <h3>Acknowledgements</h3> The authors thank the GPs who participated in this study for their time and openness during the interviews. <h3>Disclosure of Interest</h3> None declared
Evaluation of safety and activity of everolimus plus exemestane in metastatic breast cancer: a single institution experience
Authors: I. Ferrarini, I. Bertolini, S. Fancelli, C. De Angelis, A. Fontana, B. Salvadori, E. Landucci, A. Michelotti, A. Falcone
Journal: Annals of Oncology (2015)
HLA-target antigens and T-cell receptor diversity of activated T cells invading the skin during acute graft-versus-host disease
Authors: J Gaschet, MA Trevino, M Cherel, R Vivien, A Garcia-Sahuquillo, MM Hallet, M Bonneville, JL Harrousseau, R Bragado, N Milpied, H Vie
Journal: Blood (1996)
FRI0554 Young Patients with Back Pain and Maximally 1 Spondyloarthritis Feature: Is it Necessary to Test HLA-B27 or Image the Sacroiliac Joints?
Authors: P. Bakker, Z. Ez-Zaitouni, M. van Lunteren, R. van den Berg, M. de Hooge, I. Berg, R. Landewé, M. van Oosterhout, R. Ramonda, T. Huizinga, M. Reijnierse, F. van Gaalen, D. van der Heijde
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Axial SpondyloArthritis (axSpA) is a heterogeneous disease. The likelihood of diagnosis varies depending upon the presence of the specific SpA-features. It is debated whether additional examinations (i.e. HLA-B27 testing and imaging of the sacroiliac joints (SIJ)) should be performed in patients with a low suspicion of axSpA (0-1 present SpA-features) after clinical examination, physical examination, CRP/ESR measurement. <h3>Objectives</h3> To investigate if HLA-B27 testing and imaging of the SIJ is useful in young patients with back pain and maximally 1 SpA feature. <h3>Methods</h3> The SPACE cohort includes patients with chronic back pain (CBP; ≥3 months ≤2 years, onset &lt;45 years) recruited from 5 participating centres across Europe. All patients underwent full diagnostic work-up: MRI and x-rays SIJ, HLA-B27 testing and assessment of all other SpA-features. Patients were classified according to the ASAS axSpA-criteria and according to the clinical rheumatologist diagnosis. <h3>Results</h3> In this analysis, 133 patients were included. Of the 38/133 (28.6%) patients without SpA-features; 4/38 (10.5%) were classified according to the ASAS-axSpA criteria after additional investigations (table). Three of them were also diagnosed as axSpA by the rheumatologist. Four additional patients were diagnosed axSpA but did not fulfil the ASAS axSpA criteria. Of the 95/133 (71.4%) patients with 1 SpA-feature; 22/95 (23.2%) patients fulfilled the ASAS criteria via the imaging arm. SpA features in these patients were: 7 IBP, 5 IBD, 4 positive family history for SpA, 3 good response to NSAIDs, 2 raised CRP/ESR, 1 enthesitis. Seventeen of these 22 patients were also diagnosed as axSpA by the rheumatologist. Six additional patients were diagnosed axSpA but did not fulfil the ASAS axSpA criteria. <h3>Conclusions</h3> In patients with CBP and maximally 1 SpA feature after medical history, physical examination and CRP/ESR measurement, subsequent HLA-B27 testing and imaging led to fulfilment of the ASAS axSpA-criteria in 11% and 23%, respectively. In addition axSpA was the clinical diagnosis in almost twenty percent of this group. Therefore, in patients with maximally 1 SpA feature, axSpA cannot be ruled out without additional imaging and/or HLA-B27 testing. <h3>Disclosure of Interest</h3> None declared
Nuclear Topography in the Abnormal Cell of Sézary Syndrome: Observation by Freeze-Etch Electron Microscopy
Authors: Henry K. Tan, Maria Harrison, Harvey R. Gralnick
Journal: JNCI Journal of the National Cancer Institute (1974)

Freeze-etch electron microscopy revealed marked infolding in nuclei of the abnormal cells of Sézary syndrome, but no infolding in nuclei of lymphocytes, lymphoblasts, and myeloblasts.